1.Exploration and practice of building a disciplinary inspection management platform in public hospitals
Jianchun YU ; Huimin LV ; Jin YAN ; Jia ZHANG
Modern Hospital 2024;24(10):1515-1517
		                        		
		                        			
		                        			The second plenary session of the 20th Central Commission for Discipline Inspection proposed the"develop-ment of a five-year plan for information technology construction to establish a digital disciplinary inspection and supervision system that covers the entire process and all elements."This provides guidance and momentum for disciplinary inspection agencies at all levels to implement the strategic deployment of the Party's 20th National Congress regarding comprehensive and strict governance of the Party.In this context,utilizing information technology to enhance the efficiency of supervision,discipline enforcement,and accountability while ensuring the high-quality development of public hospitals has become a key task for their disciplinary inspec-tion departments.The Disciplinary Inspection Commission of a public hospital has explored the establishment of a disciplinary in-spection management platform to achieve modular management of inspection tasks.By utilizing functions such as task allocation,statistical analysis,data migration,and early warning reminders,the platform aims to improve the efficiency of disciplinary in-spection work.This approach helps address the challenges of heavy workloads and limited inspection resources in hospitals,enab-ling real-time supervision,early warning correction,and time-bound oversight,thereby providing strong support for the construc-tion of integrity in the hospital.
		                        		
		                        		
		                        		
		                        	
2.Ideal cardiovascular health and mortality: pooled results of three prospective cohorts in Chinese adults.
Yanbo ZHANG ; Canqing YU ; Shuohua CHEN ; Zhouzheng TU ; Mengyi ZHENG ; Jun LV ; Guodong WANG ; Yan LIU ; Jiaxin YU ; Yu GUO ; Ling YANG ; Yiping CHEN ; Kunquan GUO ; Kun YANG ; Handong YANG ; Yanfeng ZHOU ; Yiwen JIANG ; Xiaomin ZHANG ; Meian HE ; Gang LIU ; Zhengming CHEN ; Tangchun WU ; Shouling WU ; Liming LI ; An PAN
Chinese Medical Journal 2023;136(2):141-149
		                        		
		                        			BACKGROUND:
		                        			Evidence on the relations of the American Heart Association's ideal cardiovascular health (ICH) with mortality in Asians is sparse, and the interaction between behavioral and medical metrics remained unclear. We aimed to fill the gaps.
		                        		
		                        			METHODS:
		                        			A total of 198,164 participants without cancer and cardiovascular disease (CVD) were included from the China Kadoorie Biobank study (2004-2018), Dongfeng-Tongji cohort (2008-2018), and Kailuan study (2006-2019). Four behaviors (i.e., smoking, physical activity, diet, body mass index) and three medical factors (i.e., blood pressure, blood glucose, and blood lipid) were classified into poor, intermediate, and ideal levels (0, 1, and 2 points), which constituted 8-point behavioral, 6-point medical, and 14-point ICH scores. Results of Cox regression from three cohorts were pooled using random-effects models of meta-analysis.
		                        		
		                        			RESULTS:
		                        			During about 2 million person-years, 20,176 deaths were recorded. After controlling for demographic characteristics and alcohol drinking, hazard ratios (95% confidence intervals) comparing ICH scores of 10-14 vs. 0-6 were 0.52 (0.41-0.67), 0.44 (0.37-0.53), 0.54 (0.45-0.66), and 0.86 (0.64-1.14) for all-cause, CVD, respiratory, and cancer mortality. A higher behavioral or medical score was independently associated with lower all-cause and CVD mortality among the total population and populations with different levels of behavioral or medical health equally, and no interaction was observed.
		                        		
		                        			CONCLUSIONS
		                        			ICH was associated with lower all-cause, CVD, and respiratory mortality among Chinese adults. Both behavioral and medical health should be improved to prevent premature deaths.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Cardiovascular Diseases/prevention & control*
		                        			;
		                        		
		                        			East Asian People
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Smoking
		                        			
		                        		
		                        	
3.SWI/SNF Complex Gene Mutations Promote the Liver Metastasis of Non-small Cell Lung Cancer Cells in NSI Mice.
Lingling GAO ; Zhi XIE ; Shouheng LIN ; Zhiyi LV ; Wenbin ZHOU ; Ji CHEN ; Linlin ZHU ; Li ZHANG ; Penghui ZENG ; Xiaodan HUANG ; Wenqing YAN ; Yu CHEN ; Danxia LU ; Shuilian ZHANG ; Weibang GUO ; Peng LI ; Xuchao ZHANG
Chinese Journal of Lung Cancer 2023;26(10):753-764
		                        		
		                        			BACKGROUND:
		                        			The switch/sucrose nonfermentable chromatin-remodeling (SWI/SNF) complex is a pivotal chromatin remodeling complex, and the genomic alterations (GAs) of the SWI/SNF complex are observed in several cancer types, correlating with multiple biological features of tumor cells. However, their role in liver metastasis of non-small cell lung cancer (NSCLC) remains unclear. Our study aims to investigate the role and potential mechanisms underlying NSCLC liver metastasis induced by the GAs of SWI/SNF complex.
		                        		
		                        			METHODS:
		                        			The GAs of SWI/SNF complex in NSCLC cell lines (H1299, H23 and H460) were identified by whole-exome sequencing (WES). ARID1A knockout H1299 cell was constructed with the CRISPR/Cas9 technology. The mouse model of liver metastasis from NSCLC was established to simulate lung cancer liver metastasis and observe the metastasis rate under different gene mutation conditions. RNA sequencing and Western blot were conducted for differential gene expression analysis. Immunohistochemistry (IHC) analysis was used to assess protein expression levels of SWI/SNF-regulated target molecules in mouse liver metastases.
		                        		
		                        			RESULTS:
		                        			WES analysis revealed intracellular gene mutations. The animal experiments demonstrated a correlation between the GAs of SWI/SNF complex and a higher liver metastasis rate in immunodeficient mice. Transcriptome sequencing and Western blot analysis showed upregulated expression of ALDH1A1 and APOBEC3B in SWI/SNF-mut cells, particularly in ARID1A-deficient H460 and H1299 sgARID1A cells. IHC staining of mouse liver metastases further demonstrated elevated expression of ALDH1A1 in the H460 and H1299 sgARID1A group.
		                        		
		                        			CONCLUSIONS
		                        			This study underscores the critical role of the GAs of SWI/SNF complex, such as ARID1A and SMARCA4, in promoting liver metastasis of lung cancer cells. The GAs of SWI/SNF complex may promote liver-specific metastasis by upregulating ALDH1A1 and APOBEC3B expression, providing novel insights into the molecular mechanisms underlying lung cancer liver metastasis.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Carcinoma, Non-Small-Cell Lung/genetics*
		                        			;
		                        		
		                        			Lung Neoplasms/genetics*
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			Liver Neoplasms/genetics*
		                        			
		                        		
		                        	
4.Development and validation of a score predicting mortality for older patients with mitral regurgitation.
De-Jing FENG ; Yun-Qing YE ; Zhe LI ; Bin ZHANG ; Qing-Rong LIU ; Wei-Wei WANG ; Zhen-Yan ZHAO ; Zheng ZHOU ; Qing-Hao ZHAO ; Zi-Kai YU ; Hai-Tong ZHANG ; Zhen-Ya DUAN ; Bin-Cheng WANG ; Jun-Xing LV ; Shuai GUO ; Run-Lin GAO ; Hai-Yan XU ; Yong-Jian WU
Journal of Geriatric Cardiology 2023;20(8):577-585
		                        		
		                        			OBJECTIVE:
		                        			To develop and validate a user-friendly risk score for older mitral regurgitation (MR) patients, referred to as the Elder-MR score.
		                        		
		                        			METHODS:
		                        			The China Senile Valvular Heart Disease (China-DVD) Cohort Study functioned as the development cohort, while the China Valvular Heart Disease (China-VHD) Study was employed for external validation. We included patients aged 60 years and above receiving medical treatment for moderate or severe MR (2274 patients in the development cohort and 1929 patients in the validation cohort). Candidate predictors were chosen using Cox's proportional hazards model and stepwise selection with Akaike's information criterion.
		                        		
		                        			RESULTS:
		                        			Eight predictors were identified: age ≥ 75 years, body mass index < 20 kg/m2, NYHA class III/IV, secondary MR, anemia, estimated glomerular filtration rate < 60 mL/min per 1.73 m2, albumin < 35 g/L, and left ventricular ejection fraction < 60%. The model displayed satisfactory performance in predicting one-year mortality in both the development cohort (C-statistic = 0.73, 95% CI: 0.69-0.77, Brier score = 0.06) and the validation cohort (C-statistic = 0.73, 95% CI: 0.68-0.78, Brier score = 0.06). The Elder-MR score ranges from 0 to 15 points. At a one-year follow-up, each point increase in the Elder-MR score represents a 1.27-fold risk of death (HR = 1.27, 95% CI: 1.21-1.34, P < 0.001) in the development cohort and a 1.24-fold risk of death (HR = 1.24, 95% CI: 1.17-1.30, P < 0.001) in the validation cohort. Compared to EuroSCORE II, the Elder-MR score demonstrated superior predictive accuracy for one-year mortality in the validation cohort (C-statistic = 0.71 vs. 0.70, net reclassification improvement = 0.320, P < 0.01; integrated discrimination improvement = 0.029, P < 0.01).
		                        		
		                        			CONCLUSIONS
		                        			The Elder-MR score may serve as an effective risk stratification tool to assist clinical decision-making in older MR patients.
		                        		
		                        		
		                        		
		                        	
5.Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines.
Meng Yuan DAI ; Yan Li ZHANG ; Yu Xi SUN ; Xin LV ; Xin Xin ZHANG ; Xiu Li SUN ; Feng Qi FANG ; Ji Wei LIU ; Yun Long XIA ; Ying LIU
Chinese Journal of Cardiology 2022;50(11):1058-1063
		                        		
		                        			
		                        			Objective: To explore the incidence and risk factors of cardiovascular events in hematological neoplasms patients treated with anthracyclines in the real world. Methods: A total of 408 patients with lymphoma and leukemia, who were treated with anthracyclines during hospitalization in the First Affiliated Hospital of Dalian Medical University from January 1, 2018 to July 31, 2021, were included in this retrospective study. Patients were divided into cardiovascular event group (n=74) and non-cardiovascular event group (n=334). The primary endpoint was cardiovascular events (arrhythmia, heart failure, acute myocardial infarction etc.) after anthracyclines therapy. The secondary endpoint was all-cause mortality, cardiovascular-cause death, discontinued chemotherapy due to cardiovascular events. Multivariate regression analysis was used to investigate the risk factors of cardiovascular events. Kaplan-Meier was performed to calculate the incidence of all-cause mortality. Results: The mean age was (55.6±14.9) years, and there were 227 male patients (55.6%) in this cohort. The median follow-up time was 45 months. During follow-up, cardiovascular adverse events occurred in 74 patients (18.1%), including 45 heart failure (38 were heart failure with preserved ejection fraction), 30 arrhythmia, 4 acute myocardial infarction and 2 myocarditis/pericarditis. Multivariate regression analysis showed age (OR=1.024, 95%CI 1.003-1.045, P=0.027) and history of hypertension over 10 years (OR=2.328, 95%CI 1.055-5.134, P=0.036) were independent risk factors for the cardiovascular events. Kaplan-Meier survival curve showed mortality was significantly higher in cardiovascular event group than in non-cardiovascular event group (47.3% vs. 26.6%, P=0.001). In the cardiovascular event group, chemotherapy was discontinued in 9 cases (12.2%) due to cardiovascular events and cardiovascular death occurred in 7 cases (9.5%). Conclusions: Although heart failure is the main cardiovascular event in lymphoma and leukemia patients post anthracyclines therapy, other cardiovascular events especially arrhythmias are also common. The presence of cardiovascular events is associated with higher risk of all-cause mortality in these patients. Age and long-term hypertension are independent risk factors for cardiovascular events in lymphoma and leukemia patients after anthracyclines treatment.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Anthracyclines/adverse effects*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Heart Failure/drug therapy*
		                        			;
		                        		
		                        			Myocardial Infarction/complications*
		                        			;
		                        		
		                        			Hematologic Neoplasms/complications*
		                        			;
		                        		
		                        			Arrhythmias, Cardiac/complications*
		                        			;
		                        		
		                        			Leukemia/complications*
		                        			;
		                        		
		                        			Hypertension/complications*
		                        			
		                        		
		                        	
6.Relationship between treatment and prognosis in patients with late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation.
Le Qing CAO ; Jing Rui ZHOU ; Yu Hong CHEN ; Huan CHEN ; Wei HAN ; Yao CHEN ; Yuan Yuan ZHANG ; Chen Hua YAN ; Yi Fei CHENG ; Xiao Dong MO ; Hai Xia FU ; Ting Ting HAN ; Meng LV ; Jun KONG ; Yu Qian SUN ; Yu WANG ; Lan Ping XU ; Xiao Hui ZHANG ; Xiao Jun HUANG
Journal of Peking University(Health Sciences) 2022;54(5):1013-1020
		                        		
		                        			OBJECTIVE:
		                        			To explore the relationship between drug treatment and outcomes in patients with late-onset severe pneumonia (LOSP) after allogeneic stem cell transplantation (allo-SCT).
		                        		
		                        			METHODS:
		                        			We retrospectively analyzed the effects of the initiation time of treatment drugs, especially antiviral drugs and glucocorticoids on the clinical outcomes in 82 patients between January 2016 and August 2021 who developed LOSP after allo-SCT in Peking University People's Hospital. Univariate analysis was performed by Mann-Whitney U test and χ2 test, and multivariate analysis was performed by Logistic regression. When multiple groups (n>2) were involved in the χ2 test, Bonferroni correction was used for the level of significance test.
		                        		
		                        			RESULTS:
		                        			Of all 82 patients in this study, the median onset time of LOSP was 220 d (93-813 d) after transplantation, and the 60-day survival rate was 58.5% (48/82). The median improvement time of the survival patients was 18 d (7-44 d), while the median death time of the died patients was 22 d (2-53 d). Multivariate analysis showed that the initiation time of antiviral drugs from the onset of LOSP (< 10 d vs. ≥10 d, P=0.012), and the initiation time of glucocorticoids from antiviral drugs (< 10 d vs. ≥10 d, P=0.027) were the factors affecting the final outcome of the patients with LOSP at the end of 60 d. According to the above results, LOSP patients were divided into four subgroups: group A (antiviral drugs < 10 d, glucocorticoids ≥10 d), group B (antiviral drugs < 10 d, glucocorticoids < 10 d), group C (antiviral drugs ≥10 d, glucocorticoids ≥10 d) and group D (antiviral drugs ≥10 d, glucocorticoids < 10 d), the 60-day survival rates were 91.7%, 56.8%, 50.0% and 21.4%, respectively.
		                        		
		                        			CONCLUSION
		                        			Our study demonstrated that in patients who developed LOSP after allo-SCT, the initiation time of antiviral drugs and glucocorticoids were associated with the prognosis of LOSP, and the survival rate was highest in patients who received antiviral drugs early and glucocorticoids later. It suggested that for patients with LOSP of unknown etiology should be highly suspicious of the possibility of a secondary hyperimmune response to viral infection.
		                        		
		                        		
		                        		
		                        			Antiviral Agents/therapeutic use*
		                        			;
		                        		
		                        			Glucocorticoids/therapeutic use*
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation/methods*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Pneumonia/etiology*
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Transplantation, Homologous/adverse effects*
		                        			
		                        		
		                        	
7. Comprehensive Evaluation and Application of Experimental Sources of Variation in Gut Microbiome Sequencing Studies
Ke-Lin XU ; Yue ZHUANG ; Si-Bo ZHU ; Jiang-Li XUE ; Yan-Feng JIANG ; Zi-Yu YUAN ; Chen SUO ; Tie-Jun ZHANG ; Ming LV ; Xing-Dong CHEN ; Si-Bo ZHU ; Yan-Feng JIANG ; Jiu-Cun WANG ; Xing-Dong CHEN ; Si-Bo ZHU ; Yan-Feng JIANG ; Xing-Dong CHEN ; Chen SUO ; Tie-Jun ZHANG ; Ming LV
Chinese Journal of Biochemistry and Molecular Biology 2022;38(7):959-970
		                        		
		                        			
		                        			 Gut microbiome sequencing studies have great potential to translate microbial analysis outcomes into human health research. Sequencing strategies of 16S amplicon and whole-metagenome shotgun (WMS) are two main methods in microbiome research with respective advantages. However, how sample heterogeneity, sequencers and library preparation protocols affect the sequencing reproducibility of gut microbiome needs further investigation. This study aims to provide a reference for the selection of sequencing technologies by comparing differences in microbial composition from different sampling sites. The results of three widely adopted sequencers showed that the technical repetition correlation (r= 0. 94) was high in WMS method, while the biological repetition correlation (r = 0. 69) was low. Bray-Curtis distance identified that dissimilarity from biological replicates was larger than that of technical replicates (P<0. 001). In addition, dissimilarity and specific taxonomic profiles were observed between 16S and WMS datasets. Our results imply that homogenization is a necessary step before sample DNA extraction. The sequencers contributed less to taxonomic variation than the library preparation protocols. We developed an empirical Bayes approach that " borrowed information" in calculations and analyzed batch effect parameters using standardized data and prior distributions of (non-) parameters, which may improve population comparability between 16S and WMS and provide a basis for further application to fusion analysis of published 16S and microbial datasets. 
		                        		
		                        		
		                        		
		                        	
8.Annual financial expenditure in 24 domestic blood stations: a comparative analysis
Huixia ZHAO ; Pengkun WANG ; Hongjun CAI ; Lina HE ; Qizhong LIU ; Feng YAN ; Jianhua LI ; Jiankun MA ; Jianling ZHONG ; Chaochao LV ; Yu JIANG ; Qingpei LIU ; Li LI ; Jian ZHANG ; Weitao YANG ; Wei ZHANG ; Zhenxing WANG ; Peng WANG ; Wenjie HUANG ; Qingjie MA ; Youhua SHEN ; Zhibin TIAN ; Meihua LUN ; Mei YU
Chinese Journal of Blood Transfusion 2022;35(9):947-949
		                        		
		                        			
		                        			【Objective】 To study the annual financial expenditure in blood stations with different scales, and to establish the regression equation between blood collection units and total expenditure. 【Methods】 The annual total expenditure, the per capita cost of serving population, as well as the collection units of whole blood and apheresis platelet of 24 blood stations were collected. The financial expenditure required for collecting 10 000U blood was calculated.The statistical analysis was carried out with SPSS statistical software. 【Results】 From 2017 to 2020, the total annual financial expenditure of 24 blood stations showed an upward trend. The total expenditure among blood stations was different. The per capita cost of servicing population in the areas where the 24 blood stations were located had been increasing year by year. The 24 blood stations were divided into two grades according to the blood collection volume as 50 000 U, and the relationship equation between the blood collection volume and the annual total expenditure had been established. After testing, each equation was effective(P<0.05); There was no difference in the financial expenditure required for collecting 10 000U blood among blood stations with different scales. 【Conclusion】 From 2017 to 2020, the blood stations with an annual collection volume more than 50 000 U demonstrated a higher financial expenditure and the per capita cost of serving population than those <50 000 U. The blood collection volume of blood stations is significantly correlated with the annual total expenditure and the per capita cost of serving population.
		                        		
		                        		
		                        		
		                        	
9. Expert consensus on prevention and cardiopulmonary resuscitation for cardiac arrest in COVID-19
Wei SONG ; Yanhong OUYANG ; Yuanshui LIU ; Heping XU ; Feng ZHAN ; Wenteng CHEN ; Jun ZHANG ; Shengyang YI ; Jie WEI ; Xiangdong JIAN ; Deren WANG ; Xianjin DU ; Ying CHEN ; Yingqi ZHANG ; Shuming XIANYU ; Qiong NING ; Xiang LI ; Xiaotong HAN ; Yan CAO ; Tao YU ; Wenwei CAI ; Sheng'Ang ZHOU ; Yu CAO ; Xiaobei CHEN ; Shunjiang XU ; Zong'An LIANG ; Duohu WU ; Fen AI ; Zhong WANG ; Qingyi MENG ; Yuhong MI ; Sisen ZHANG ; Rongjia YANG ; Shouchun YAN ; Wenbin HAN ; Yong LIN ; Chuanyun QIAN ; Wenwu ZHANG ; Yan XIONG ; Jun LV ; Baochi LIU ; Xiaojun HE ; Xuelian SUN ; Yufang CAO ; Tian'En ZHOU
Asian Pacific Journal of Tropical Medicine 2021;14(6):241-253
		                        		
		                        			
		                        			 Background: Cardiopulmonary resuscitation (CPR) strategies in COVID-19 patients differ from those in patients suffering from cardiogenic cardiac arrest. During CPR, both healthcare and non-healthcare workers who provide resuscitation are at risk of infection. The Working Group for Expert Consensus on Prevention and Cardiopulmonary Resuscitation for Cardiac Arrest in COVID-19 has developed this Chinese Expert Consensus to guide clinical practice of CPR in COVID-19 patients. Main recommendations: 1) A medical team should be assigned to evaluate severe and critical COVID-19 for early monitoring of cardiac-arrest warning signs. 2) Psychological counseling and treatment are highly recommended, since sympathetic and vagal abnormalities induced by psychological stress from the COVID-19 pandemic can induce cardiac arrest. 3) Healthcare workers should wear personal protective equipment (PPE). 4) Mouth-to-mouth ventilation should be avoided on patients suspected of having or diagnosed with COVID-19. 5) Hands-only chest compression and mechanical chest compression are recommended. 6) Tracheal-intubation procedures should be optimized and tracheal-intubation strategies should be implemented early. 7) CPR should be provided for 20-30 min. 8) Various factors should be taken into consideration such as the interests of patients and family members, ethics, transmission risks, and laws and regulations governing infectious disease control. Changes in management: The following changes or modifications to CPR strategy in COVID-19 patients are proposed: 1) Healthcare workers should wear PPE. 2) Hands-only chest compression and mechanical chest compression can be implemented to reduce or avoid the spread of viruses by aerosols. 3) Both the benefits to patients and the risk of infection should be considered. 4) Hhealthcare workers should be fully aware of and trained in CPR strategies and procedures specifically for patients with COVID-19. 
		                        		
		                        		
		                        		
		                        	
10.Altered Splicing in Stable Cell Strains Expressing Mini-hF9 Gene with Nonsense Mutation.
Gang WANG ; Wen-Wen SUN ; Lv-Kai ZHU ; Yan-Chun MA ; Xia-Lin ZHANG ; Jian-Hua ZHANG ; Juan REN ; Xiu-Yu QIN ; Lin-Hua YANG ; Bao-Feng CHAI
Journal of Experimental Hematology 2021;29(1):228-232
		                        		
		                        			OBJECTIVE:
		                        			To investigate the molecular mechanism in stable cell strains expressing Mini-hF9 gene with nonsense mutation.
		                        		
		                        			METHODS:
		                        			Mini-hF9 gene and its nonsense mutants were transfected into HeLa cells independently, and stable cell strains were obtained after G418 resistance screening and monoclonal transformation. The altered splicing and protein expression of mRNA in Mini-hF9 gene in stable cell strains were detected by using RT-PCR and Western blot.
		                        		
		                        			RESULTS:
		                        			The wild type and nonsense mutated human coagulation factor IX stable cell strains were constructed successfully, which were named HeLa-F9-WT, HeLa-F9-M1 and HeLa-F9-M2. Only normal splicing Norm was detected in the wild-type cell strain HeLa-F9-WT; Norm and Alt-S1 splicing were detected in HeLa-F9-M1; while Norm, Alt-S1 and Alt-S2 splicing were detected in HeLa-F9-M2.
		                        		
		                        			CONCLUSION
		                        			The nonsense associated altered splicing (NAS) pathway, which generated alternately spliced transcripts, might be triggered in coagulation factor IX gene with nonsense mutation.
		                        		
		                        		
		                        		
		                        			Codon, Nonsense
		                        			;
		                        		
		                        			Factor IX/metabolism*
		                        			;
		                        		
		                        			HeLa Cells
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			RNA Splicing
		                        			;
		                        		
		                        			RNA, Messenger/metabolism*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail